It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
Amyloid-like aggregates of the microtubule-associated protein Tau are associated with several neurodegenerative disorders including Alzheimer’s disease. The existence of cellular machinery for the removal of such aggregates has remained unclear, as specialized disaggregase chaperones are thought to be absent in mammalian cells. Here we show in cell culture and in neurons that the hexameric ATPase valosin-containing protein (VCP) is recruited to ubiquitylated Tau fibrils, resulting in their efficient disaggregation. Aggregate clearance depends on the functional cooperation of VCP with heat shock 70 kDa protein (Hsp70) and the ubiquitin-proteasome machinery. While inhibition of VCP activity stabilizes large Tau aggregates, disaggregation by VCP generates seeding-active Tau species as byproduct. These findings identify VCP as a core component of the machinery for the removal of neurodegenerative disease aggregates and suggest that its activity can be associated with enhanced aggregate spreading in tauopathies.
Tau aggregates are associated with several neurodegenerative disorders. In this work, I. Saha and colleagues show that valosin-containing protein (VCP) recruited to Tau fibrils disaggregates them. However, this process comes at a cost: it generates seeding-active Tau species as byproduct.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details










1 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA (GRID:grid.513948.2) (ISNI:0000 0005 0380 6410)
2 Max Planck Institute for Biological Intelligence, Molecular Neurodegeneration Group, Martinsried, Germany (GRID:grid.4372.2) (ISNI:0000 0001 2105 1091); Max Planck Institute for Biological Intelligence, Department of Molecules – Signaling – Development, Martinsried, Germany (GRID:grid.4372.2) (ISNI:0000 0001 2105 1091); University of Cologne, Center for Anatomy, Faculty of Medicine and University Hospital Cologne, Cologne, Germany (GRID:grid.6190.e) (ISNI:0000 0000 8580 3777)
3 Max Planck Institute of Biochemistry, Department of Structural Molecular Biology, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Peking University, State Key Laboratory of Protein and Plant Gene Research, School of Life Sciences and Peking-Tsinghua Center for Life Sciences, Beijing, China (GRID:grid.11135.37) (ISNI:0000 0001 2256 9319)
4 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X)
5 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Max Planck Institute of Biochemistry, Department of Structural Molecular Biology, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3)
6 Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA (GRID:grid.513948.2) (ISNI:0000 0005 0380 6410); Max Planck Institute of Biochemistry, Department of Structural Molecular Biology, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); University Medical Center Göttingen, Institute of Neuropathology, Göttingen, Germany (GRID:grid.411984.1) (ISNI:0000 0001 0482 5331); University of Göttingen, Cluster of Excellence “Multiscale Bioimaging: from Molecular Machines to Networks of Excitable Cells” (MBExC), Göttingen, Germany (GRID:grid.7450.6) (ISNI:0000 0001 2364 4210)
7 Max Planck Institute of Biochemistry, Department of Structural Molecular Biology, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X)
8 University of Texas Southwestern Medical Center, Center for Alzheimer’s and Neurodegenerative Diseases, Peter O’Donnell Jr. Brain Institute, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121); Princeton University, Department of Chemical and Biological Engineering, Princeton, USA (GRID:grid.16750.35) (ISNI:0000 0001 2097 5006)
9 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Boehringer Ingelheim International GmbH, Ingelheim, Germany (GRID:grid.420061.1) (ISNI:0000 0001 2171 7500); ViraTherapeutics GmbH, Rum, Austria (GRID:grid.420061.1)
10 University of Texas Southwestern Medical Center, Center for Alzheimer’s and Neurodegenerative Diseases, Peter O’Donnell Jr. Brain Institute, Dallas, USA (GRID:grid.267313.2) (ISNI:0000 0000 9482 7121)
11 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Aligning Science Across Parkinson’s (ASAP) Collaborative Research Network, Chevy Chase, USA (GRID:grid.513948.2) (ISNI:0000 0005 0380 6410); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3)
12 Max Planck Institute of Biochemistry, Department of Cellular Biochemistry, Martinsried, Germany (GRID:grid.418615.f) (ISNI:0000 0004 0491 845X); Munich Cluster for Systems Neurology (SyNergy), Munich, Germany (GRID:grid.452617.3); Carl von Ossietzky University Oldenburg, School of Medicine and Health Sciences, Oldenburg, Germany (GRID:grid.5560.6) (ISNI:0000 0001 1009 3608); University Medical Center Groningen, University of Groningen, Department of Biomedical Sciences of Cells and Systems, Groningen, The Netherlands (GRID:grid.4494.d) (ISNI:0000 0000 9558 4598)